Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations

Journal of Medicinal Chemistry

Volumn 39, Issue 6, 1996, Pages 1271-1280

  Piper, James R ^a   Johnson, Cheryl A ^a   Krauth, Charles A ^a   Carter, Ronald L ^a   Hosmer, Carla A ^a   Queener, Sherry F ^b   Borotz, Susan E ^c   Pfefferkorn, Elmer R ^c  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 METHYL 5 DEAZAPTERIDINE DERIVATIVE; 2,4 DIAMINOPTERIDINE DERIVATIVE; 2,4 DIAMINOQUINAZOLINE DERIVATIVE; ANTIPROTOZOAL AGENT; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID ANTAGONIST; LIVER ENZYME; PIRITREXIM; PTERIDINE DERIVATIVE; PYRIMETHAMINE; QUINAZOLINE DERIVATIVE; TRIMETHOPRIM; TRIMETREXATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; LIPOPHILICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; REVIEW; TOXOPLASMA GONDII;

ANIMALS; ANTI-INFECTIVE AGENTS; FOLIC ACID ANTAGONISTS; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA; TOXOPLASMOSIS; TRIMETREXATE;

EID: 0029875638     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950760y     Document Type: Review

References (38)

1. Tenth International Symposium on Chemistry and Biology of Pteridines, held March 21-26, 1993, in Orange Beach, AL. A published summary is listed herein as ref 22.
2. Presented in part at the 207th American Chemical Society National Meeting, held March 13-17, 1994, in San Diego, CA; Abstract MEDI 242.
3. Lane, H. C. (moderator) with Laughon, B. E.; Falloon, J.; Kovacs, J. A.; Davey, R. T., Jr.; Folis, M. A.; Masur, H. (discussants). NIH Conference. Recent advances in the management of AIDS-related opportunistic infections. Ann. Intern. Med. 1994, 120, 945-955.
4. Sande, M. A. Antimicrobial therapy of infections in patients with AIDS-an overview. J. Antimicrob. Chemother. 1989, 23, 63-6.
5. Tuazon, C. U. Toxoplasmosis in AIDS patients. J. Antimicrob. Chemother. 1989, 23 (Suppl. A), 77-82.
6. Gazard, B. G. Pneumocystis carinii pneumonia and its treatment in patients with AIDS. J. Antimicrob. Chemother. 1989, 23 (Suppl. A), 67-75.
7. Kovacs, J. A ; Allegra, C. J.; Swan, J. C.; Drake, J. C.; Parrillo, J. E.; Chabner, B. A.; Masur, H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob. Agents Chemother. 1988, 32, 430-433.
8. Kovacs, J. A.; Allegra, C. J.; Kennedy, S.; Swan, J. C.; Drake, J.; Parrillo, J. E.; Chabner, B.; Masur, H. Efficacy of trimetrexate. a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am. J. Trop. Med. Hyg. 1988, 39, 491-496.
9. Edman, J. C.; Edman, U.; Cao, M.; Lundgren, B.; Kovacs, J. A.; Santi, D. V. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8625-8629.
10. Walzer, P. D.; Kim, C. K; Foy, J. M.; Linke, M. J.; Cushion, M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1988, 72, 96-103.
11. Kovacs, J. A. Advances in the therapy of toxoplasmosis, pp 947-949. In Lane, H. C., Moderator. Recent advances in the management of AIDS-related opportunistic infections. Ann. Intern. Med. 1994, 120, 945-955.
12. Araujo, F. G.; Lin, T.; Remington, J. S. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J. Infect. Dis. 1993, 167, 494-497.
13. Falloon, J. Treatment of Pneumocystis carinii pneumonia, pp 946-947. In Lane, H. C., moderator. Recent advances in the management of AIDS-related opportunistic infections. Ann. Intern. Med. 1994, 720, 945-955.
14. (a) Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
15. (b) Chio, L.-C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
16. 50 values for inhibitory agents against human and rat liver DHFRs and confirm that the rodent enzyme is an acceptable model for the human enzyme in drug screening.
17. Hynes, J. B.; Tomažič, A.; Kumar, A.; Kumar, V; Freisheim, J. H. Inhibition of human dihydrofolate reductase by 2,4-diaminoquinazolinee bearing simple substituents on the aromatic ring, J. Heterocycl. Chem. 1991, 28, 1981-1986.
18. Allegra, C. J.; Kovacs, J. A.; Drake, J. C.; Swan, J. C.; Chabner, B. A.; Masur, H. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J. Clin. Invest. 1987, 79, 478-482.
19. Pfefferkorn, E. R.; Eckel, M. E.; McAdams, E. Toxoplasma gondii: In vivo and in vitro studies of a mutant resistant to arprinocid N-oxide, Exp. Parasitol. 1988, 65, 282-289.
20. Bartlett, M. S.; Shaw, M.; Navaran, P.; Smith, J. W.; Queener, S. F. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimtcrob. Agents Chemother. 1990, 39, 2436-2441.
21. Mills, J.; Masur, H. AIDS-related infections. Sci. Am. 1990,263, 50-57.
22. (a) Piper, J. R.; Montgomery, J. A. 6-(Bromomethyl)-2,4-diaminopteridine. U.S. Pat. 4077 957, 1978.
23. (b) Piper, J. R.; Montgomery, J. A. Method of making pteridine compounds. U.S. Pat 4079 056, 1978.
24. Piper, J. R.; Johnson, C. A.; Hosmer, C. A.; Carter, R. L.; Pfefferkorn, E. R.; Borotz, S. E.; Queener, S. F. Lipophilic antifolates as candidates against opportunistic infections. Adv. Exp. Med. Biol. 1993, 338, 429-433.
25. Piper, J. R.; Montgomery, J. A, Preparation of 6-(bromomethyl)-2,4-pteridinediamine hydrobromide and its use in improved syntheses of methotrexate and related compounds. J. Org. Chem. 1977, 42, 208-211.
26. Montgomery, J. A.; Piper, J. R.; Elliott, R. D.; Roberts, E. C.; Temple, Carroll, Jr.; Shealy, Y. F. Derivatives of 2,4-diamino-6-methylpteridine. J. Heterocycl. Chem. 1979, 16, 537-539.
27. 10-methylfolic acid. J. Med. Chem. 1986, 29, 1080-1087.
28. (a) Piper, J. R.; Montgomery, J. A. A convenient synthesis of 10-deazaaminopterin via a pteridine ylide. J. Med. Chem. 1980, 23, 320-321.
29. (b) Piper, J. R.; Johnson, C. A.; Otter, G. M.; Sirotnak, F. M. Synthesis and antifolate evaluation of 10-ethyl-5-methyl-5,10-dideazaaminopterin and an alternative synthesis of 10-ethyl-1O-deazaaminopterin (Edatrexate). J. Med. Chem. 1992, 35, 3002-3006.
30. Piper, J. R.; Malik, N. D.; Rhee, M. S.; Galivan, J.; Sirotnak, F. M. Synthesis and antifolate evaluation of the 10-propargyl derivatives of 5-deazafolic acid, 5-deazaaminopterin, and 5-methyl-5-deazaaminopterin. J. Med. Chem. 1992, 35, 332-337.
31. Piper, J. R.; Johnson, C. A.; Malik, N. D.; McGuire, J. J.; Otter, G. M.; Sirotnak, F. M. Studies on analogues of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain. J. Med. Chem. 1993, 36, 4161-4171.
32. Piper, J. R.; Ramamurthy, B.; Johnson, C. A.; Maddry. J. A.; Otter, G. M.; Sirotnak, F. M. Further evaluation of 5-alkyl-5-deaza antifolates. 5-Propyl- and 5-butyl-5-deaza analogues of aminopterin and methotrexate. J. Heterocycl. Chem. 1995, 32, 1205-1212.
33. Piper, J. R.; McCaleb, G. S.; Montgomery, J. A.; Kishuk, R. L.; Gaumont, Y.; Thorndike, J.; Sirotnak, F. M. Synthesis and antifolate activity of 5-methyl-5,10-dideaza analogues of aminopterin and folic acid and an alternative synthesis of 5,10-dideazatetrahydrofolic acid, a potent inhibitor of glycinamide ribonucleotide formyltransferase. J. Med. Chem. 1988, 31, 2164-2169.
34. Davoll, J.; Johnson, A. M. Quinazoline analogues of folie acid. J. Chem. Soc. C 1970, 997-1002.
35. Elslager, E. F.; Johnson, J. L.; Werbel, L. M. Folate antagonists. 20. Synthesis and antitumor and antimalarial properties of trimetrexate and related 6-[(phenylamino)methyl]-2,4-quinazolinediamines. J. Med. Chem. 1983, 26, 1753-1760.
36. Gangjee, A; Vasudevan, A.; Queener, S. F.; Kisliuk, R. L. 6-Substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. J. Med. Chem. 1995, 38, 1778-1785.
37. Krishnamurthy, S. A. A highly efficient and general N-monomethylation of functionalized primary amines via formylationborane·methyl sulfide reduction. Tetrahedron Lett. 1982, 23, 3315-3318.
38. Gangjee, A.; Devraj, R.; Lin, F.-T. Synthesis of 2,4-diamino-5,10-dideaza nonclassical antifolates. J. Heterocycl. Chem. 1991, 28, 1747-1751.